A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Switching from a Regimen of Dolutegravir and Either Emtricitabine/Tenofovir Alafenamide or Emtricitabine/Tenofovir Disoproxil Fumarate to a Fixed Dose Combination of Bictegravir/ Emtricitabine/Tenofovir Alafenamide in HIV-1 Infected Subjects who are Virologically Suppressed Save

Date Added
June 13th, 2017
PRO Number
Pro00066778
Researcher
Eric Meissner
Keywords
HIV / AIDS
Summary

This clinical research study is looking for men and women 18 years of age or older to test and evaluate the safety and effectiveness of an investigational combination medication for adults living with HIV.
Volunteers must be diagnosed with HIV-1 and on certain treatment regimens for HIV for at least the past 3 months. Those who qualify will take study medication for at least 48 weeks (almost 1 year). This medication will either be the investigational medication or an FDA approved medication for HIV. Subjects will receive all study-related care at no cost.

Institution
MUSC
Recruitment Contact
Tamara Jenkins
(843) 792-5491
saundert@musc.edu

Elucidating Mechanisms of Treatment Relapse for Interferon-Free HCV Therapy Save

Date Added
August 18th, 2015
PRO Number
Pro00046669
Researcher
Eric Meissner
Keywords
Digestive System, HIV / AIDS, Immune System, Infectious Diseases, Liver
Summary

Treatment of chronic hepatitis C virus (HCV) infection is now possible with all oral medications. While most patients achieve a sustained virologic response (SVR) after treatment, synonymous with cure, some patients relapse after treatment for reasons that are unclear. The goal of this research is to understand how a person's immune system changes during treatment of HCV infection with all oral therapy, and how these changes might impact the chances of relapse after treatment. To address these questions, blood and clinical information will be collected from study participants over the course of receiving standard of care treatment for HCV infection. This blood and clinical information will be used to conduct laboratory research focused on the immune system.

Institution
MUSC
Recruitment Contact
Stephanie Warth
843-792-5491
warth@musc.edu

Change_preferences

-- OR --

Create_login